Triple

T1169604
Position Surface form Disambiguated ID Type / Status
Subject Ionis Pharmaceuticals E24882 entity
Predicate notableProduct P1448 FINISHED
Object Waylivra
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
 E133691 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Waylivra | Statement: [Ionis Pharmaceuticals, notableProduct, Waylivra]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Waylivra
Context triple: [Ionis Pharmaceuticals, notableProduct, Waylivra]
  • A. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • B. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • C. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • D. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • E. Versonnex
    Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Waylivra
Triple: [Ionis Pharmaceuticals, notableProduct, Waylivra]
Generated description
Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Waylivra
Target entity description: Waylivra is a prescription antisense oligonucleotide therapy used to treat familial chylomicronemia syndrome (FCS) by reducing triglyceride levels in the blood.
  • A. Darzalex
    Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
  • B. Anpezan
    Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
  • C. Vumerity
    Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
  • D. Aduhelm
    Aduhelm is an Alzheimer’s disease drug developed by Biogen that targets amyloid-beta plaques in the brain.
  • E. Versonnex
    Versonnex is a small commune in the Ain department of eastern France, located near the Swiss border in the Pays de Gex region.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bce821b481908bc278a3fa7973f4 completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac668562788190ac5f8d081a46b2ee completed March 7, 2026, 5:55 p.m.
NEDg Description generation batch_69ac67a07f28819096fcd7b767e07a63 completed March 7, 2026, 6 p.m.
NED2 Entity disambiguation (via description) batch_69ac6826ef4c81909fc077bfba22b16f completed March 7, 2026, 6:02 p.m.
Created at: March 1, 2026, 7:45 p.m.